EXPONENT INC. - 10-Q Filing Summary
Business Context and Reporting Period
Company: Exponent, Inc. (EXPO)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended July 4, 2025
Business Overview: An engineering and scientific consulting firm providing solutions to complex problems across more than 90 technical disciplines. The company operates two reportable segments: Engineering & other scientific, and Environmental and health.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $141,962 | $140,536 | $287,469 | $285,469 |
| Operating Income | $17,177 | $35,744 | $61,609 | $66,457 |
| Net Income | $26,553 | $29,227 | $53,203 | $59,369 |
| Diluted EPS | $0.52 | $0.57 | $1.03 | $1.15 |
| Cash & Equivalents (End of Period) | $231,801 | $203,262 | $231,801 | $203,262 |
| Operating Cash Flow (YTD) | $43,496 | $58,771 | $43,496 | $58,771 |
| Capital Expenditures (YTD) | ($4,028) | ($2,628) | ($4,028) | ($2,628) |
Liquidity & Debt: The company maintains a strong balance sheet with $231.8 million in cash and cash equivalents as of July 4, 2025. There is no long-term debt reported; liabilities consist primarily of operating lease obligations ($80.3 million total) and deferred compensation plan liabilities ($117.6 million).
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 revenue increased 1.0% year-over-year, driven by higher billing rates in the Engineering segment, partially offset by a 6% decrease in billable hours and a 3% decrease in technical full-time equivalent employees.
- Profitability Decline: Operating income dropped 51.9% in Q2 2025 compared to Q2 2024. This was primarily due to a $16.1 million increase in deferred compensation expense (offset by a corresponding gain in other income) and higher occupancy costs from a land lease extension in Arizona.
- Segment Performance:
- Engineering & other scientific: Revenue up 2.1%; Operating income down 1.9% due to lower utilization (74% vs 77%).
- Environmental and health: Revenue down 4.9%; Operating income down 3.3% due to lower billable hours in life sciences and chemical regulatory services.
- Other Income: Q2 2025 "Other income, net" surged 398.7% to $19.6 million, largely due to a $17.0 million gain from changes in the fair value of deferred compensation plan assets.
Outlook, Risks, and Unusual Items
- Unusual Items: The significant fluctuation in operating income is driven by non-cash accounting adjustments related to the deferred compensation plan. The company recognized a $16.96 million increase in plan asset value in Q2 2025, recorded as both compensation expense and miscellaneous income. Additionally, a $0.64 million decrease in rental income occurred due to the loss of a tenant in the Silicon Valley facility.
- Guidance & Commentary: Management expects compensation expenses to rise as they adjust salaries to market conditions and add talent. Other operating expenses are expected to grow due to infrastructure investments. The company remains focused on share repurchases and dividends to enhance shareholder value.
- Risks: Key risks include demand fluctuations based on economic conditions, the timing of engagements, and the ability to attract and retain key employees. Foreign currency exposure exists for operations in the UK, China, Hong Kong, and Singapore, though hedging is not currently utilized.
- Subsequent Events: On July 31, 2025, the Board declared a cash dividend of $0.30 per share, payable September 19, 2025.
Investor Verification Checklist
- Deferred Compensation Volatility: Verify the sustainability of earnings by analyzing the impact of the deferred compensation plan's fair value changes on both operating expenses and other income.
- Utilization Rates: Monitor the trend in billable hours and utilization rates (down to 72% in Q2 2025) to assess future revenue pressure.
- Arizona Lease Impact: Confirm the long-term impact of the extended land lease in Arizona, which adds significant non-cash rent expense through 2043.
- Share Repurchases: Track the remaining authorization for share repurchases ($61.6 million remaining as of July 4, 2025) and the pace of buybacks.
- Segment Mix: Observe the shift in revenue mix between the Engineering segment (growing) and Environmental/Health segment (declining) to understand sector-specific demand.